Search

Your search keyword '"Nogova L"' showing total 208 results

Search Constraints

Start Over You searched for: Author "Nogova L" Remove constraint Author: "Nogova L" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
208 results on '"Nogova L"'

Search Results

1. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

2. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

3. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential

4. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

5. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

6. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

7. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

8. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

9. P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases

10. KS02.7.A Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors

11. The fading relevance of the quantity of brain metastases in patients with non-small cell lung cancer

14. Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors

15. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

16. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

17. The biological effect of small-scale ROS1 aberrations: An in silico analysis

18. Small-scale ROS1 aberrations: Functional impact and therapeutic potential

19. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort

20. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

23. 1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance

27. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

29. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data

30. Small Cell Lung Cancer - Filling the gap between science and patients

31. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup

32. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

35. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability

36. Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway

37. OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients

38. Genomic and clinical characterization of non-small cell lung cancer (NSCLC) patients harboring mutations in FGFR2 and FGFR3

39. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance

40. FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered squamous NSCLC

41. Impact on KRAS-subtypes and TP53 mutations on the prognostic value of KRAS/KEAP1 comutations in non-small cell lung cancer (NSCLC)

44. FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress)

45. BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer

47. Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations

48. Rogaratinib in patients with advanced urothelial carcinomas selected for tumor FGFR mRNA expression and impact of mutations in the FGFR signaling pathway

50. EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results

Catalog

Books, media, physical & digital resources